Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03618992
Other study ID # 1806645760
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date August 1, 2018
Est. completion date May 31, 2020

Study information

Verified date June 2021
Source University of Arizona
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This will be a multi-visit study that will take approximately 3 hours in total. Up to 200 subjects from the BUMC Valley Fever and BUMC Dermatology clinics will be enrolled in this study and assigned to one of three cohorts according to timeline of oral anti-fungal therapy. Subjects in Cohort 1 will be randomized to apply topical cholesterol-containing moisturizers to the skin, hair and lips on either the right or left side of the body daily. Measurements of skin barrier function, appearance of skin and hair, and hair samples will be obtained at baseline and at 4 week follow-up visits. Cohorts 2 and 3 will be observational groups at differing points in oral antifungal treatment regimen. Subjects will be randomized to have measurements of skin barrier function and hair and skin characteristics obtained from either the right or left side of the body at baseline and at monthly follow-up visits.


Description:

Coccidioidomycosis, also known as Valley Fever, is a fungal condition most commonly seen in Arizona and can affect multiple organs, including the skin, lung, bone, joints, and central nervous system. Oral antifungal therapy such as fluconazole is the first-line medication to treat coccidioidomycosis. Through the investigator's clinical observations at the Valley Fever Center for Excellence, nearly all patients who have been placed on systemic azole treatment show some extent of cosmetic changes in their skin and hair, such as dry skin, chapped lips, hair loss, and change in hair characteristics. The goals of the study are to 1) understand the cosmetic changes in the skin and hair in patients initiating and discontinuing long-term oral antifungals, and 2) to examine whether cholesterol-based commercially-available moisturizers for the skin and for the hair can improve the cosmetic appearance better than a vehicle without these cholesterol ingredients.


Recruitment information / eligibility

Status Terminated
Enrollment 14
Est. completion date May 31, 2020
Est. primary completion date May 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women, age 18 or older - Patients who have been diagnosed with coccidioidomycosis (valley fever) requiring oral anti-fungal medications such as but not limited to fluconazoles - Able to comprehend and read the English language Exclusion Criteria: - Subject does not fit inclusion criteria - Children younger than 18 years of age - Pregnant women - Prisoners or those that are cognitively impaired - Those with known allergies or intolerance to ingredients in the topical formulations - Subject is unwilling or unable to comply with study procedures - Unable to read or comprehend English

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Cholesterol-containing moisturizers
Commercially-available cholesterol containing topical formulations to be applied daily to the scalp, skin, lips, eyelashes, and eyebrows. Available from Skin Actives Scientific (www.skinactives.com).

Locations

Country Name City State
United States University of Arizona - Banner University Medicine Dermatology Tucson Arizona
United States Valley Fever Center for Excellence Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
University of Arizona

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Hair characteristics Evaluate caliber and density of scalp, eyebrow and eyelash hair through hair samples and photos. Up to one year
Primary Skin barrier function - Transepidermal water loss (TEWL) Assess skin barrier function through measurement of transepidermal water loss (in g/m^2h) using a commercially-available, non-invasive device. Up to one year
Primary Skin barrier function - Stratum corneum hydration Assess skin barrier function through measurement of stratum corneum hydration (in arbitrary units) using a commercially-available, non-invasive device. Up to one year
Primary Skin barrier function - Sebum Assess skin barrier function through measurement of sebum (in micrograms/cm^2) using a commercially-available, non-invasive device. Up to one year
Primary Skin barrier function - pH Assess skin barrier function through measurement of stratum corneum pH (in pH units) using a commercially-available, non-invasive device. Up to one year
See also
  Status Clinical Trial Phase
Completed NCT04208321 - Safety and Pharmacokinetics of VT-1598 Phase 1
Terminated NCT00614666 - Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment Phase 1/Phase 2
Recruiting NCT02190266 - Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
Completed NCT00796809 - Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis N/A
Withdrawn NCT02908334 - Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis Phase 2
Completed NCT00423267 - POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED) Phase 3
Completed NCT00690092 - A Multi-center Study of Spherule-Derived Coccidioidin Phase 3
Withdrawn NCT04809649 - SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole Phase 2
Completed NCT03908632 - An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)
Terminated NCT02663674 - Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever) Phase 4
Completed NCT03059992 - Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Phase 3
Completed NCT00002325 - A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common N/A